Startseite Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats

  • Baran Ghezelbash , Nader Shahrokhi EMAIL logo , Mohammad Khaksari , Firouz Ghaderi-Pakdel und Gholamreza Asadikaram
Veröffentlicht/Copyright: 14. Februar 2020
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Hormone Molecular Biology and Clinical Investigation
Aus der Zeitschrift Hormone Molecular Biology and Clinical Investigation Band 41 Heft 1

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is the main common cause of chronic liver disease. The aim of this study is to evaluate the effect of Shilajit, a medicine of Ayurveda, on the liver damage caused by NAFLD.

Materials and methods

Forty male Wistar rats, after being established as fatty liver models by feeding a high-fat diet (HFD, 12 weeks), were divided randomly into five groups as follows: control (standard diet), vehicle (HFD + distilled water), high-dose Shilajit (HFD + 250 mg/kg Shilajit), low-dose Shilajit (HFD + 150 mg/kg Shilajit) and pioglitazone (HFD + 10 mg/kg pioglitazone). The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), glucose and liver glutathione peroxidase (GPx), superoxide dismutase (SOD) activity, malondialdehyde (MDA) levels, liver weight, and histopathological manifestation outcomes were measured after the 2-week intervention.

Results

Shilajit treatment significantly reduced the values of AST and ALT, TG, TC, LDL, glucose, liver weight, and steatosis, and instead, increased high-density lipoprotein (HDL) compared with the vehicle group (p < 0.05). Further, Shilajit treatment improved the adverse effects of HFD-induced histopathological changes in the liver as compared with the vehicle group (p < 0.001). MDA level and GPx activity increased but SOD activity decreased in the vehicle group compared with the control group (p < 0.05), while treatment with Shilajit restored the antioxidant/oxidant balance toward a significant increase in the antioxidant system in the Shilajit group (p < 0.05).

Conclusions

These findings suggest that Shilajit improved the histopathological NAFLD changes in the liver and indicated the potential applicability of Shilajit as a potent agent for NAFLD treatment.

Keywords: non-alcoholic fatty liver disease; oxidative stress; pioglitazone; Shilajit

Acknowledgment

This work is part of the Ph.D. thesis of Ms. Ghezelbash at the Department of Physiology.

  1. Author statement

  2. Research funding: The present study was financially supported by the Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran.

  3. Conflict of interest: All the authors declare no conflicts of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: This study was approved by the Medical Ethics Committee of Kerman University of Medical Sciences (Approval No: IR. KMU. REC. 1394. 681).

References

[1] Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.10.1186/s12916-017-0806-8Suche in Google Scholar PubMed PubMed Central

[2] Farrell GC, Wong VW, Chitturi S. NAFLD in Asia – as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307–18.10.1038/nrgastro.2013.34Suche in Google Scholar PubMed

[3] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:1388-9.10.1002/hep.28584Suche in Google Scholar PubMed

[4] Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17(Suppl):S186–90.10.1046/j.1440-1746.17.s1.10.xSuche in Google Scholar PubMed

[5] Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016;8:75.10.4137/CMT.S18885Suche in Google Scholar PubMed PubMed Central

[6] Yki-Jarvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104–11.10.1007/s00125-016-3944-1Suche in Google Scholar PubMed

[7] Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–82.10.1002/hep.24268Suche in Google Scholar PubMed

[8] Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.10.1002/hep.21327Suche in Google Scholar PubMed

[9] Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–43.10.1038/35007508Suche in Google Scholar PubMed

[10] Kopelman PG, Finer N. Reply: is obesity a disease? Int J Obes Relat Metab Disord. 2001;25:1405–6.10.1038/sj.ijo.0801791Suche in Google Scholar PubMed

[11] Sharma P, Jha J, Shrinivas V, Dwivedi LK, Suresh P, Sinha M. Shilajit: evalution of its effects on blood chemistry of normal human subjects. Anc Sci Life. 2003;23:114–9.Suche in Google Scholar

[12] Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK. Shilajit: a review. Phytother Res. 2007;21:401–5.10.1002/ptr.2100Suche in Google Scholar

[13] Gangwar SS, Thakur R, Sharma R, Tilak A. Shilajit a medicinal mystery to cure the un-cure disease. Imperial J Interdisciplinary Res. 2016;3:1544–7.Suche in Google Scholar

[14] Stohs SJ. Safety and efficacy of shilajit (mumie, moomiyo). Phytother Res. 2014;28:475–9.10.1002/ptr.5018Suche in Google Scholar

[15] Goel RK, Banerjee RS, Acharya SB. Antiulcerogenic and antiinflammatory studies with shilajit. J Ethnopharmacol. 1990;29:95–103.10.1016/0378-8741(90)90102-YSuche in Google Scholar

[16] Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Intern. 2007;27:708–15.10.1111/j.1478-3231.2007.01497.xSuche in Google Scholar PubMed

[17] Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.10.1002/hep.20701Suche in Google Scholar PubMed

[18] Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the World. Clin Liver Dis. 2016;20:205–14.10.1016/j.cld.2015.10.001Suche in Google Scholar PubMed

[19] Ji J, Zhang L, Wang P, Mu YM, Zhu XY, Wu YY, et al. Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture. Exp Toxicol Pathol. 2005;56:369–76.10.1016/j.etp.2005.02.003Suche in Google Scholar PubMed

[20] de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21:219–23.10.1054/clnu.2001.0529Suche in Google Scholar PubMed

[21] Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:360–9.10.1055/s-0028-1091980Suche in Google Scholar PubMed PubMed Central

[22] Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010;52:586–93.10.1016/j.jhep.2010.01.003Suche in Google Scholar PubMed PubMed Central

[23] Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732–7.10.2337/diacare.21.5.732Suche in Google Scholar

[24] Ghosal S, Bhattacharya SK. Antioxidant defense by native and processed shilajit – a comparative study. Indian J Chem. 1996;35B:127–32.Suche in Google Scholar

[25] Tripathi YB, Shukla S, Chaurasia S, Chaturvedi S. Antilipid peroxidative property of Shilajit. Phytother Res. 1996;10:269–70.10.1002/(SICI)1099-1573(199605)10:3<269::AID-PTR817>3.0.CO;2-3Suche in Google Scholar

[26] Trivedi N, Mazumdar B, Bhatt J, Hemavathi K. Effect of shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats. Indian J Pharmacol. 2004;36:373.Suche in Google Scholar

[27] Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009;50:1217–26.10.1002/hep.23126Suche in Google Scholar

[28] Kececi M, Akpolat M, Gulle K, Gencer E, Sahbaz A. Evaluation of preventive effect of shilajit on radiation-induced apoptosis on ovaries. Arch Gynecol Obstet. 2016;293:1255–62.10.1007/s00404-015-3924-6Suche in Google Scholar

[29] Bhattacharya SK, Sen AP, Ghosal S. Effects of shilajit on biogenic free radicals. Phytotherapy Res. 1995;9:56–9.10.1002/ptr.2650090113Suche in Google Scholar

[30] Jarukamjorn K, Jearapong N, Pimson C, Chatuphonprasert W. A high-fat, high-fructose diet induces antioxidant imbalance and increases the risk and progression of nonalcoholic fatty liver disease in mice. Scientifica. 2016;2016.10.1155/2016/5029414Suche in Google Scholar

[31] Ismail NA, Okasha SH, Dhawan A, Abdel-Rahman AO, Shaker OG, Sadik NA. Antioxidant enzyme activities in hepatic tissue from children with chronic cholestatic liver disease. Saudi J Gastroenterol. 2010;16:90.10.4103/1319-3767.61234Suche in Google Scholar

[32] Crawford A, Coombes JS, Kunde DA, Ahuja KD, Robertson LK, Ball MJ, et al. Glutathione peroxidase, superoxide dismutase and catalase activities in children with chronic hepatitis. Adv Biosci Biotechnol. 2011;26:2806–13.10.1093/ndt/gfq828Suche in Google Scholar

[33] Chrobot AM, Szaflarska-Szczepanik A, Drewa G. Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit. 2000;6:713–8.Suche in Google Scholar

[34] Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527–605.10.1152/physrev.1979.59.3.527Suche in Google Scholar

[35] Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54:287–93.10.1016/j.ajme.2017.09.001Suche in Google Scholar

[36] Carrasco-Gallardo C, Guzman L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142.10.1155/2012/674142Suche in Google Scholar

[37] Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther. 2004;3:333–41.10.1177/1534735404270578Suche in Google Scholar PubMed

Received: 2019-07-14
Accepted: 2019-10-24
Published Online: 2020-02-14

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Special Issue: ‘Liver Metabolic Diseases and Hepatocellular Carcinoma: New Hormonal and Clinical Insights’ / Editors: Gérard S. Chetrite and Bruno Féve
  2. Editorial Preface
  3. Preface to special issue on “Liver Metabolic Diseases and Hepatocellular Carcinoma: New Hormonal and Clinical Insights”
  4. Original Article
  5. Aromatase in normal and diseased liver
  6. Review Articles
  7. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms
  8. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models
  9. Metalloproteinases in non-alcoholic fatty liver disease and their behavior in liver fibrosis
  10. Hypothyroidism and nonalcoholic fatty liver disease – a chance association?
  11. Mini-Review Article
  12. The impact of steatosis on liver regeneration
  13. Regular Issue
  14. Original Articles
  15. Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats
  16. 3-Iodothyronamine and 3,5,3′-triiodo-L-thyronine reduce SIRT1 protein expression in the HepG2 cell line
  17. Machine learning as new promising technique for selection of significant features in obese women with type 2 diabetes
  18. Implementation of a novel self-induced promoter for the expression of pharmaceutical peptides in Escherichia coli: YY(3-36) peptide
  19. Comparison of the effect of 12- and 24-session cardiac rehabilitation on physical, psychosocial and biomedical factors in ischemic heart disease patients
  20. The stimulation protocol in poor responder IVF; a minimal or high-dose stimulation? – A meta-analysis
  21. Review Articles
  22. Cell free DNA: revolution in molecular diagnostics – the journey so far
  23. Genitourinary syndrome of menopause (GSM) and laser VEL: a review
https://doi.org/10.1515/hmbci-2019-0040
Schlagwörter für diesen Artikel
non-alcoholic fatty liver disease; oxidative stress; pioglitazone; Shilajit

Artikel in diesem Heft

  1. Special Issue: ‘Liver Metabolic Diseases and Hepatocellular Carcinoma: New Hormonal and Clinical Insights’ / Editors: Gérard S. Chetrite and Bruno Féve
  2. Editorial Preface
  3. Preface to special issue on “Liver Metabolic Diseases and Hepatocellular Carcinoma: New Hormonal and Clinical Insights”
  4. Original Article
  5. Aromatase in normal and diseased liver
  6. Review Articles
  7. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms
  8. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models
  9. Metalloproteinases in non-alcoholic fatty liver disease and their behavior in liver fibrosis
  10. Hypothyroidism and nonalcoholic fatty liver disease – a chance association?
  11. Mini-Review Article
  12. The impact of steatosis on liver regeneration
  13. Regular Issue
  14. Original Articles
  15. Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats
  16. 3-Iodothyronamine and 3,5,3′-triiodo-L-thyronine reduce SIRT1 protein expression in the HepG2 cell line
  17. Machine learning as new promising technique for selection of significant features in obese women with type 2 diabetes
  18. Implementation of a novel self-induced promoter for the expression of pharmaceutical peptides in Escherichia coli: YY(3-36) peptide
  19. Comparison of the effect of 12- and 24-session cardiac rehabilitation on physical, psychosocial and biomedical factors in ischemic heart disease patients
  20. The stimulation protocol in poor responder IVF; a minimal or high-dose stimulation? – A meta-analysis
  21. Review Articles
  22. Cell free DNA: revolution in molecular diagnostics – the journey so far
  23. Genitourinary syndrome of menopause (GSM) and laser VEL: a review
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 23.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2019-0040/html
Button zum nach oben scrollen